Everolimus + Lonafarnib for Progeria

This trial tests a combination of two drugs, everolimus (also known as Afinitor, Votubia, or Zortress) and lonafarnib, to determine their effectiveness in treating progeria, a rare genetic disorder causing rapid aging in children. Researchers aim to find the right dose of everolimus that can be safely combined with lonafarnib and assess the combination's effectiveness in managing the condition. Participants must have a confirmed diagnosis of progeria, exhibit its symptoms, and currently take lonafarnib. As a Phase 1, Phase 2 trial, this research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking advancements in progeria treatment.

You may need to stop taking certain medications that affect the metabolism of lonafarnib or if you are on chronic systemic corticosteroids or other immunosuppressive agents. However, topical or inhaled steroids are allowed, and those with endocrine deficiencies can take necessary steroid doses.

Earlier studies have shown promise in using everolimus and lonafarnib together. Research indicates that lonafarnib alone can benefit patients with progeria by increasing body weight, reducing stiffness in the heart and blood vessels, and improving bone strength. Adding everolimus to lonafarnib might offer additional heart health benefits, especially with the correct dosage.

Researchers are excited about Everolimus and Lonafarnib for treating Progeria because these drugs work together in a novel way to potentially improve outcomes. Unlike current treatments that mainly focus on managing symptoms, Lonafarnib works by inhibiting farnesyltransferase, which can reduce the buildup of defective proteins in cells. Everolimus adds another layer by targeting the mTOR pathway, which is involved in cell growth and aging. This combination aims to address the underlying cellular issues of Progeria, offering hope for more effective management of this rare condition.

Research has shown that lonafarnib alone holds potential for treating progeria. Studies have found that it can help patients gain weight, reduce heart and blood vessel stiffness, and improve bone strength. In mice with progeria, lonafarnib resulted in 100% survival by the end of studies. This trial will administer a combination of everolimus and lonafarnib to participants. Adding everolimus to lonafarnib might enhance these benefits, as lab evidence suggests this combination works better than lonafarnib alone. This combination targets the root causes of the disease more effectively, potentially leading to better outcomes for people with progeria.¹³⁵⁶⁷